Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 7.10
- Piotroski Score 2.00
- Grade Overweight
- Symbol (XBIT)
- Company XBiotech Inc.
- Price $7.45
- Changes Percentage (5.67%)
- Change $0.4
- Day Low $7.09
- Day High $7.46
- Year High $9.96
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.
- Last Earnings 07/06/2021
- Ex-Dividend for 5/16 Dividend 07/15/2021
- Dividend Payable 07/23/2021
- Today N/A
- Next Earnings (Estimated) 11/07/2024
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.01
- Trailing P/E Ratio -6.67
- Forward P/E Ratio -6.67
- P/E Growth -6.67
- Net Income $-24,557,000